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Abstract
Purpose This paper aims to present a novel framework for
reducing energy consumption in pharmaceutical manufactur-
ing processes, with a primary focus on parenterals production.
The framework supports (a) the design of optimal energy-
saving solutions, (b) the execution and implementation and (c)
the comparison of designed and actual performance as a post-
implementation control. In selecting promising options,
multiobjective criteria are defined for comprehensive
decision-making which considers not only energy savings,
but also other aspects such as good manufacturing practice
(GMP), risk, and workers’ safety.
Methods and Framework In the framework, five phases were
defined in total, with three for design and two for execution and
control, respectively. In the three design phases, options are
generated, evaluated and selected step by step, with appropriate
evaluation criteria covering financial as well as non-financial
aspects. The roles of various stakeholders, e.g., Operations,
Engineering, or Quality Assurance, are defined for each phase
in order to enable smooth and certain decision-making.
Case Study and Results A case study was performed in the
parenterals production plant at Hoffmann-La Roche in
Kaiseraugst. Twelve energy efficiency ideas were generated
and, after the screening and selection process, the three most
promising options from the multiobjective Pareto optimiza-
tion were implemented to reduce the total plant’s energy
consumption by 2.5 %.
Conclusions The framework enabled the systematic generation
and selection of various options, which helped in the allocation
of company resources in a prioritized and thus effectivemanner.
Keywords Energy efficiency . Pharmaceutical
manufacturing .Multiobjective decision-making .
Parenterals production . Industrial case study
Introduction
Energy efficiency is becoming more and more important in the
pharmaceutical industry as energy prices and supply uncertain-
ty increase. Especially for operations in countries such as
Switzerland, primary resources have to be imported which are
susceptible to political crises and natural disasters. As a conse-
quence of the Fukushima Daiichi nuclear disaster, several
countries decided to phase out nuclear power. For example, in
2010, nuclear power accounted for 38 % of the electricity in
Switzerland [1] and will have to be substituted by other sources
in the upcoming decades. This restructuring of the energy sector
is expected to lead to greater uncertainty on the energy market
and consequently to higher prices. Under these conditions,
energy conservation is being promoted which has, in addition
to environmental benefits, other non-neglectable benefits, such
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as better workplace conditions, productivity, safety, shareholder
value, and public relations [2]. Thus, the effects of these con-
ditions as part of a company’s sustainability strategy influence
shareholders and have been recently quantified, e.g., in the
Dow Jones Sustainability Index [3].
To improve a company’s energy efficiency, the various
sites, buildings—including plants as well as office and labo-
ratory buildings—have to be integrated in the company’s
strategy. In plants/chemical manufacturing facilities, the nec-
essary energy savings can be achieved either by means of
energy efficient design or by analyzing and retrofitting
existing plants/facilities. Methods and frameworks for energy
conservation are practically tradition in the chemical bulk
industry. Recently developed methods for structured ap-
proaches with different stages for the design and evaluation
under environmentally friendly conditions are described in
chemical process design and development by Sugiyama
et al. [4] and Chen et al. [5]. Hoffmann et al. investigated
decision-making under uncertainty [6] and uses the concept of
Pareto optimization for determining the most promising pro-
cess options [7]. These methods were mainly developed for
commodity chemicals and continuous processes, while batch
processes are used for specialty chemicals and the pharma-
ceutical industry. Albrecht et al. [8] incorporates this charac-
teristic and proposes a design framework of environmentally
friendly batch processes as an extension of the work of
Sugiyama et al. [4]. In their joint work, Heinzle et al. and
Koller et al. describe a procedure for ecological and economic
assessment during the process design stage for fine chemicals
and active pharmaceutical ingredient (API) production in [9,
10]. A method for assessing integral resource consumption in
a multipurpose API production plant is shown in van der Vorst
et al. [11]. With the aim of waste minimization, Raymond
applied life cycle assessment (LCA) to solvent used in API
production, and revealed the importance of solvent recovery
regarding cradle-to-grave environmental impacts [12].
Furthermore, various authors have described investigations
to improve the energy efficiency of parts of buildings and
various unit operations, i.e., individual energy-saving solu-
tions. With the aim of energy optimization, modeling methods
for multipurpose batch plants have been published by Bieler
et al. [13, 14] and Szijjarto et al. [15]. Galitsky et al. describe
for the US Environmental Protection Agency (EPA) [2] a set
of individual methods to improve energy efficiency in phar-
maceutical buildings, ranging from offices to production fa-
cilities. Shamkishore et al. delineate different opportunities for
energy efficiency in pharmaceutical manufacturing, e.g., for
light, motors, and steam traps [16]. Liu [17] assesses the
energy flows of an office and a pharmaceutical production
building and proposes advantageous options to reduce energy
consumption, in particular for heating and HVAC (heating,
ventilation and air conditioning) systems. Graf highlights
various strategies for the energy efficient production of
pharmaceutical water [18]. Regarding energy audit, which is
becoming popular to improve energy efficiency in a company,
Zhi-dong et al. [19] proposes a procedure and key factors to be
considered for the pharmaceutical manufacturers. In summa-
ry, various tools and recommendations have become available
for designing and retrofitting chemical and pharmaceutical
production processes which consider energy consumption.
However, in order to turn these theories into practice, compa-
nies still need a business model/standardized procedure, that
defines how to execute these design/re-design methods with
consideration on good manufacturing practice (GMP), in ad-
dition to energy reduction.
In this work, a framework for energy optimization in the
pharmaceutical industry was developed with a focus on par-
enterals manufacturing. It supports (a) the design and evalua-
tion of optimal energy-saving solutions, (b) the execution and
implementation and (c) the comparison of designed and actual
performance as a post-implementation control. In the frame-
work, five phases are defined in total, with three for design
and two for execution and control, respectively. In the three
design phases, options are generated, evaluated, and selected
step by step, with appropriate multiobjective evaluation
criteria covering financial as well as non-financial aspects,
i.e., energy savings, GMP, worker’s safety and comfort. This
development extends across several phases and allows for
screening for the best options using a funnel-concept; in-
creased knowledge and level of detail is taken into account
by more extensive evaluation criteria and only the most ap-
propriate options are finally implemented. The concept of
Pareto optimization as a trade-off method is used to support
systematic and non-subjective decision-making. Special atten-
tion is paid to GMP regulations, which serve as a strong
constraint to prevent any negative impact on product quality.
In each phase the business process is supported by a so-called
RACI scheme which defines roles and rights of the various
stakeholders involved as responsible, accountable, consulted,
and informed and which is specially adapted to the needs in
the pharmaceutical industry. The proposed framework is dem-
onstrated on the parenterals production plant at Hoffmann-La
Roche in Kaiseraugst, Switzerland. In this case study, 12
energy efficiency ideas were generated and then subjected to
step-by-step screening in the three design phases to success-
fully implement the three most promising options based on
multiobjective Pareto optimization.
Framework
Figure 1 shows the proposed framework for the reduction of
energy consumption in a pharmaceutical production plant.
Five phases are defined for generating options comprehen-
sively, selecting, and implementing promising ones with ho-
listic consideration of various consequences and finally
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evaluating actual performance. For each phase, the following
elements are defined: evaluation criteria of options, expected
investigation time per option, tolerance of evaluation results
and roles and rights of various stakeholders.
Each phase in Fig. 1 has a characteristic function with its
ownmechanisms, actions and evaluation criteria. In Phase
I, possible options are brainstormed, characterized in a
qualitative manner, and then passed on to Phase II
without any eliminations. In Phase II, decisions are
taken for the first time in order to eliminate inferior
options based on quantitative evaluations, which are
simple yet cover a wide range of aspects. In Phase III,
the final selection of superior options is made based on
detailed and focused assessment; these options are then
implemented in Phase IV. Phase V is defined for com-
paring expected and actual performance as a post-
implementation check. Information on measures not im-
plemented is collected and stored during this phase so
that the knowledge will be available for future
implementation.
There are a number of key concepts realized in our frame-
work. One is the stepwise selection approach in Phases II and
III, where all options are first screened using simple indicators,
and then superior ones are selected based on detailed evalua-
tion. This “funnel” system helps companies focus only on
promising options and thus deploy company resources in
an effective manner. Another concept is the knowledge
database in Phase V, which also contains deferred or eliminat-
ed ideas that can be used for other design cases or at a later
time. This element of knowledge management provides the
company with an opportunity for continuous improvement
within or even beyond the site in the production network.
In parenterals production, saving energy is a cross-
functional topic and thus stakeholders from multiple business
units are involved. In the field of business process manage-
ment, there is a method termed RACI where the following
four roles and rights are distinguished for the various players
involved in an activity [20]:
– Responsible (R): The individual who actually processes
the activity as a “doer”
– Accountable (A): The individual who makes the decision
and provides the required resources, e.g., manpower or
budget
– Consulted (C): The individual who is to be consulted
before an activity proceeds to the next phase
– Informed (I): The individual who is informed about the
activity but not required in the process
In this framework, RACI is applied for Engineering,
Quality Assurance (QA), Operations and Finance, which
are the major stakeholders throughout the five phases in
Fig. 1.
Phase I: Generate and Characterize Options
The key mission of the first phase is a structured, self-driven
and focused generation of options. For assistance in this
challenging task, we have defined a Sankey diagram as a
primary mechanism, among other conventional approaches
such as Pinch technology, e.g., [21], and a literature study,
e.g., [2, 16–18]. A Sankey diagram visualizes the energy
flows of a process using different thicknesses to indicate the
amount of energy and different colors to represent different
energy types, e.g., steam or electricity. In such a representa-
tion, one can easily identify parts of processes which are
energy intensive and focus on option generation.
A hierarchical Sankey diagram is applied to parenterals pro-
cesses. The following adaptations are proposed in order to
support the structured generation of energy-saving measures.
First, a hierarchical perspective is proposed, i.e., site, building,
module, sub-module, and further down to sub-sub-module.
Phases
Phase I:
Generate and 
characterize 
options
Phase II:
Evaluate and 
eliminate options
Phase III:
Identify optimum
options
Phase IV:
Implement
options
Phase V:
Perform post-
implementation 
control
Criteria
• Effort
• Effect
• Investment
• Energy
savings
• Cost savings
• GMP
• Safety
• Workplace
conditions
• NPV
• GMP and
safety risk
• Budget
• Timeline
• Matching
expectations
• Replication
potential
Investigation 
time per option 2–8 man-hours 8–24 man-hours 40–80 man-hours Days to months 2–24 man-hours
Tolerance n/a ±50% ±30% ±10% n/a
RACI
Eng. A/R R R R A/R
Ops. R A A A R
QA C C C C C
Finance - C C I C
D D
Fig. 1 Proposed framework for
energy optimization including
different stages of multiobjective
evaluations and decision-making.
Eng. Engineering; Ops.
Operations and equipment owner;
QA Quality Assurance
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Second, it is important to distinguish between modules which
are active only during production (processes), e.g., filling or
lyophilization systems, and ones which are always running
(infrastructure), e.g., HVAC systems or water for injection
(WFI) and purified water loops. This distinction makes it possi-
ble to visualize the proportion of variable and constant energy
consumption for production and infrastructure, respectively, and
can help determine the direction energy optimization is to take.
The generated options are then characterized with regard to
the degree of effort required and the effect gained by imple-
mentation. A simple classification of “high” or “low” is used
for the “effort” and “effect” categories. For this initial and
qualitative assessment, various aspects need to be considered
such as monetary or energy aspects, impacts on productivity,
GMP relevance or workers’ safety. In this phase, no decisions
or eliminations are forced as too little information is available
and the evaluation is based on qualitative criteria.
Experts from Engineering generate and characterize
alternatives; Operations and QA can contribute to
assessing the feasibility of the ideas as well as all possible
consequences. Operations and Engineering are responsi-
ble and accountable for this phase, and QA needs to be
consulted before Phase II is commenced. The overall
duration for generating and characterizing one option is
expected to be 2–8 man-hours for all stakeholders in the
process (Engineering, Operations, QA, Finance and other
staff). The whole landscape of generated options can be
summarized in a simple two-by-two matrix showing effort
and effect. This matrix is passed on to the next phase
without any eliminations.
Phase II: Evaluate and Eliminate Options
The focus of Phase II is the first-time evaluation of all options
generated in Phase I and elimination of inferior ones. Simple
models are developed for each option which are then evaluated
using the six criteria shown in Fig. 1, i.e., investment cost, energy
savings, cost savings, GMP risk, safety and workplace condi-
tions. A decision is forced for the first time so that only superior
ideas are selected, as is indicated by the “D” symbol in Fig. 1.
The first task is to estimate the potential impacts of the
options with modeling and simulation approaches. A few
simplifications can be made in this phase, e.g., static instead
of dynamic modeling, best case and worst case estimations, or
the application of rules of thumb, e.g., Biegler et al. [21]. Data
for these calculations can be obtained from various sources,
e.g., the machine supplier, measurements [22] and retrofit data
[12, 14, 15], literature [18, 23–25], and information from other
plants. Access to such data is crucial for creating shortcut
models in a timely manner, which are to be refined with more
elaborate data in the next phase.
The second task of Phase II is to evaluate the performance
of the options using the following multiobjective indicators,
which are also shown in Fig. 1 and Table 1:
& Investment in monetary units, taking into account engi-
neering and material costs
& Energy savings in GJ equivalents per year
& Cost savings in monetary units per year with gross
yield/gross benefit and increased costs such as main-
tenance and labor
Table 1 Evaluation indicators for GMP, safety and working conditions used in Phase II: option evaluation/elimination (with color codes). The scoring
system is case-specific from the case study in this article and can vary case by case
Quantitative 
indicators
1/Investment 0% 1% 2% 3% 4–100% 
Energy 
savings 
0–5% 6–10% 11–20% 21–50% 51–100% 
Cost savings 0–5% 6–10% 11–20% 21–50% 51–100% 
Qualitative 
indicators 
Score 1 2 3 4 5 
GMP High risk Low risk No risk Improvement
High  
improvement
Safety 
Very  
negative 
Negative
No 
change 
Positive 
Very  
positive 
Workplace 
conditions 
Very  
negative 
Negative
No 
change 
Positive 
Very  
positive 
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In addition to these quantitative assessments, the following
aspects are evaluated on a qualitative basis:
& GMP risk
& Workers’ safety
& Workplace conditions
For each of these categories, an overall assessment is
performed as to whether the option has a negative or positive
impact during and after implementation. Such a qualitative
valuation approach may vary from company to company. One
approach is to use a simple scale from one to five, representing
very negative, negative, neutral, positive and very positive,
respectively. This scale will be demonstrated in the case study.
One technical measure can save energy in its various forms,
such as electricity, steam, or cooling water; and for aggregat-
ing these different savings there are two different approaches,
which are interchangeable [26]. One is to calculate the equiv-
alent amount of reduced emissions such as CO2, e.g., Global
Warming Potential (GWP) [27], while the other is to trace
back to the primary energy source such as crude oil, e.g.,
Cumulative Energy Demand (CED) [28] and Energy
Weighting Factors (EWF). The latter is a Roche internal
methodology but similar concepts can be found in the EPA’s
national energy performance ratings [29] and in Jiménez-
González and Overcash [25], in which an LCA of the energy
sub-modules is performed. The choice of aggregation method
depends on the strategy of the company or the site considered.
In case of Roche Engineering Basel/Kaiseraugst, the EWF is
becoming the standard approach with its own site-specific
values, and for each form of energy there is a converting factor
for the equivalent GJ of primary energy which is easier to
understand for non-experts than the CO2 equivalents.
The final task of Phase II is to select the most promising
options based on six indicator results with so-called Pareto
optimization, used by Hoffmann et al. [6, 7]. To make all six
categories comparable, the indicator values are normalized by
the maximum, i.e., best value. The normalized values are
given by
eAi
j ¼ A
j
i
max
k A
j
k
 
ð1Þ
where Ai
j is the value of the evaluation indicator i and the idea j
and eAji the normalized value. For the investment cost, the
inverse value (Ai
j−1) can be used in order to have the best idea
of the maximum. Using these normalized results, so-called
Pareto optimal options are identified, i.e. a set of options
which are not dominated by any other options in at least one
category. Mathematically, this can be expressed as Option 2
being Pareto inferior to Option 1 if eA
1
i ≥eA2i for all categories
i=1, … n and eA
1
i >
eA2i for at least one i. Pareto optimum
options are to be investigated further in the next phase. Inferior
ones are eliminated here, but may be retained as ideas for
reconsideration at a later point in time when sufficient re-
sources become available. As the scoring system is based on
the maximum value of an indicator the values in Table 1 can
vary case by case and can be adapted as appropriate for the
respective cases. To enable the timely screening of all possible
ideas, the investigation time allocated is set at 8 to 24 man-
hours in total per idea, and the evaluation tolerance is ±50 %.
The actual work in this phase is performed by Engineering,
which also includes experts in safety issues, and Operations
has the right to make decision on alternatives. QA and Finance
need to be consulted in assessing particularly the GMP risk
and monetary performance, respectively.
Phase III: Identify Optimum Options
The goal of Phase III is to identify optimum options for the
implementation, using more detailed data, models and evalu-
ation indicators. The elaboration of the models includes re-
placement of static models with dynamic ones, e.g., consider-
ation of seasonal changes and the use of measurement data
instead of heuristic values.
The evaluation indicators of this phase are the net present
value (NPV) as well as the combined GMP and safety risk.
The NPV [21] aggregates the investment cost and cost savings
criteria from Phase II with consideration of the discount rate in
the future, which can be calculated by
NPV ¼ −Invþ
X
t¼1
n CFt
1þ rð Þt ð2Þ
where Inv is the investment cost, CFt the cash flow in the year
t, n the number of years for the evaluation and r the discount
rate. Taking into account the time value of money, the
NPV is one of the most detailed economic indicators of
an investment project and thus widely used in industry.
Values of t, n and r are typically defined in companies
as a standard, while Inv and CF in a year t are calcu-
lated based on the model. All evaluation categories
considered in Phase II are reflected in the NPV: Inv
also covers costs for preventing any issues associated
with safety, GMP or working conditions; CF reflects
benefits achieved by monetary and energy savings.
An analytical method termed Failure Mode and Effect
Analysis (FMEA) is applied for quantifying risks related to
different kinds of aspects, especially safety and GMP. It is one
of the recommended risk analysis methods from the health
authorities in the ICH Q9 [30] and broadly used in the phar-
maceutical industry. In an FMEA, various failure modes of a
process such as “valve defect” are identified and then the risk
is assessed for each failure mode, resulting in the risk priority
number (RPN) which is calculated by
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RPN ¼ Severity Occurrence Detectability ð3Þ
where Severity accounts for a consequence of the failure mode,
such as potential impact on product quality; Occurrence for the
frequency of the failure, such as once a year; Detectability for
the ability to detect the failure, such as annual maintenance or
revalidation. Usually, an integer classification such as 2, 4, 6, 8,
10 is applied for each term with ascending importance, whereas
scaling differs depending on company internal guidelines. The
FMEA characterizes each option with different failure modes
and corresponding RPN numbers, and a maximum RPN of an
option is selected to represent the worst consequence.
Using the results of these two indicators, Pareto optimal
options are identified considering the NPVand RPN as objec-
tive functions for maximization and minimization, respective-
ly. Based on this Pareto analysis, the final decision with
consideration of available resources and timing is made as to
which option(s) to implement. In several situations, options
that are identified as Pareto inferior can also be selected for
implementation or, in the opposite case, some of the Pareto
optimal ideas could be deferred. Compared to the previous
phase, the accepted error tolerance of the evaluation results is
reduced from ±50 to ±30%. All activities in this critical phase,
i.e., modeling, evaluation and decision-making, would require
40 to 80 man-hours per option performed by various experts.
The RACI structure is the same as in Phase II.
Phase IV: Implement Options
The options selected in the previous phase are finalized as a
design and implemented in Phase IV. The evaluation indica-
tors from the previous phase, i.e., the NPV and RPN, are
updated with new information, and the evaluation tolerance
is further reduced from ±30 to ±10 %. Financing has to be
planned in advance and additional budgets dedicated, for
example, to quality, workers’ safety and workplace conditions,
considered. The appropriate timing needs to be defined which
considers production and maintenance schedules. While op-
erational changes, such as the adjustment of parameters, can
be performed parallel to production, hardware changes, such
as the replacement of equipment, may well require
interrupting production for some time. Major changes may
be necessary during plant maintenance especially if the infra-
structure (e.g., media supply or air conditioning) is to be
modified since the entire production building is affected. In
most cases, GMP-related activities are to be performed along
with implementation, such as technical change management,
qualification & validation, documentation, SOP updates and
training. Performance of the implemented options needs to be
monitored intensively in the initial period, and special atten-
tion should be paid to any unforeseen events or reactions.
When initial troubles are too difficult to solve, it might
become necessary to make a decision to change or stop
implementation. Learning from failures, though, is important
from the perspective of knowledge management, and thus
such experience is to be passed on to the next phase: post-
implementation control. Depending on the option, e.g., soft-
ware versus hardware changes, this phase can take from days
to months. In the RACI, R and A remain the same from Phase
III, while QA is consulted for the change approval and
Finance is informed of the outcome.
Phase V: Perform Post-Implementation Control
The main aim of this phase is to maintain the continuity of the
improvement activity by comparing expected and realized per-
formances and identifying further improvement opportunities. To
obtain the big picture of the “before and after” situation, refresh-
ing the Sankey diagram initially created in Phase I is a useful
approach. Furthermore, some of the evaluation indicators in
Phases II and III, such as energy savings or the RPN, are updated
for a detailed view. If there is a gap between the expectation and
the result, a root cause analysis should be performed to remove
the source of the problem rather than attempt additional tempo-
rary solutions. Deferred or eliminated options in Phases II and III
can be reconsidered in case greater energy savings are needed in
order to reach a certain target value. Such deferred or eliminated
options may be suitable for implementation in other plants and
sites. Furthermore, the framework itself can be revised and
improved by, for example, adding new or modifying indicators,
adjusting the working hours and RACI case- or company-
specific. This kind of information exchange and knowledge
management within the company is an essential part of contin-
uous improvement not only for energy savings but also for other
themes in general, in particular in the Pharmaceutical Quality
System [31]. This phase takes 2–24 h, depending on the option
as simple feedback is less time intensive than a measurement
campaign. This activity is performed by Operations and
Engineering, who are also accountable for the outcome, and
QA as well as Finance are consulted to draw conclusions.
Roche Parenterals Production Kaiseraugst
Located on Hoffmann-La Roche Ltd.’s site in Kaiseraugst,
Switzerland, PKau (Parenterals Production Kaiseraugst) is
one of the newest facilities for manufacturing sterile drug
products in Europe. The building, shown in Fig. 2a, has a
gross floor area of 12,900 m2 and consists of four production
modules: compounding, liquid vials (shown in Fig. 2b), ly-
ophilized vials, and prefilled syringes. Design activities started
in 2006, followed by the construction of the building and
machine installation, which were completed in 2009. The total
investment amounted to approximately CHF 200 million.
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Since then, various start-up activities have been performed,
such as qualification/validation, creating SOPs, training and
hosting health authority inspections. Commercial production
started in 2012, and during the ramp-up to 2014, PKau will
play a major role in Roche’s global drug product manufactur-
ing network.
PKau features a few technical highlights. For example,
isolator and Restricted Access Barrier System (RABS) tech-
nologies are applied in aseptic filling processes for the preven-
tion of product contamination by minimizing particle concen-
tration and excluding microorganisms. A grade D environment
is maintained for the isolators/RABS, laboratories, offices and
storage rooms, which is where most of the supporting activities
take place. For the most part, the energy and media systems are
designed redundantly so that production can proceed even if
the energy andmedia systems are interrupted. Eachmodule has
its own independent HVAC system, which means that modules
can be shut down individually for maintenance while others
remain in operation. At the moment all the products are bio-
logics, i.e., the active pharmaceutical ingredients are based on
biologically produced proteins, which require strict control of
the production environment.
Parallel to the implementation of these technologies to
maximize GMP compliance and meet diverse customer
requirements, e.g., Japan Quality [32, 33], deliberations were
also made with regard to energy savings. External experts
were also involved, and various ideas were generated and
implemented, such as high-efficiency light bulbs, heat recov-
ery systems using condensed steam, and top-performance
ventilation engines. During the start-up, however, several
opportunities were discovered for further minimization of
energy consumption. PKau management has a vast interest
in continuous improvement [34] and has therefore decided to
improve energy efficiency within the building along with the
method described in the “Framework” section.
Case Study
Phase I
To guide the option generation process, the hierarchical
Sankey diagram shown in Fig. 3 was created according to
the description in “Phase I: Generate and Characterize
Options”. The preliminary version of Fig. 3 was presented
elsewhere [35]. It visualizes the five energy sources provided
from the Kaiseraugst site to the PKau building (Fig. 2a) in
different colors as well as their expected consumptions
Fig. 2 Introducing parenterals
production Kaiseraugst of F.
Hoffmann-La Roche Ltd.: a
facility exterior; b filling line of
liquid vials using isolator
technologies are found in first
floor
Liquid N2
H2O-
ethylene glycol
Site level
Building level
Module level
S
ub
-m
od
ul
e
le
ve
l Compounding
Liquid vials
Prefilled syringes
Lyophilized vials
Production processes
Cooling waterSteamElectricity
Storage
rooms
Highly pur.
steam sys.
WFI 
system
HVAC 
system Other
Infrastructure
Support areas
Fig. 3 Sankey diagram of PKau
process systems with hierarchical
perspective. At the module level,
units included in the production
processes are performed batch-
wise, while the ones in the
infrastructure are running
continuously
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relative to each other for 2012: liquid nitrogen, electricity,
steam, H2O-ethylene glycol (−8 °C/−3 °C cooling loop) and
cooling water (6 °C/12 °C cooling loop).
It is possible to identify various proportions of energy
consumption from Fig. 3: electricity, steam, and cooling water
account for most of PKau’s energy consumption; liquid nitro-
gen and H2O-ethylene glycol, on the other hand, make up only
a fraction of this. This fact led to energy efficiency options
which focus on electricity, steam, and cooling water. At
“module level”, it is evident that most of the energy is con-
sumed in infrastructure and only a fraction in processes. A
sensitivity analysis has proven that this will also be the case in
the future following the start-up phase. This situation led to the
decision to focus on generating energy efficiency options
within the scope of the infrastructure rather than within the
scope of the production process. At the sub-module level of
the infrastructure only the largest consumers are shown, i.e.,
highly purified steam, WFI, and HVAC systems. The latter is
the most energy-intensive sub-module because in parenterals
production high air change rates (20 h−1 for a grade D envi-
ronment in the rooms around Production; 10 h−1 in other grade
D rooms) with an exactly specified room temperature and
humidity are required to minimize particles and microbial
concentration. This has also been described for other pharma-
ceutical manufacturing buildings [2, 17]. The WFI and highly
purified steam systems are 100 % redundant and thus have a
higher base consumption.
According to the RACI scheme in this phase, an expert
group from Engineering, Operations, and QA generated and
characterized the 12 feasible options in Phase I. These options
are shown in Fig. 4 and described below with their Phase I
evaluations.
& Option 1 is the installation of the enthalpy control system
shown in Fig. 5. It is an energy monitoring and control
system for the HVAC system to minimize energy costs,
i.e., measuring the enthalpy of the outside and the exhaust
air to find the optimum mixture of recirculated air system,
heat recovery system, heating, cooling and humidifica-
tion. The effort required to install such a system would
result in the highest cost savings of all measures. More
detailed information for this option can be found in the
Appendix.
& In Option 2, the WFI subloop was changed from perma-
nent cooling to on-demand cooling by training the opera-
tors to stop the system more effectively. In the WFI
subloop 80 °C WFI is cooled to 20 °C for compounding
and heated back up to 80 °C for re-introduction into the
WFI main loop. Reducing the operating times of this
system saves steam and cooling water. The effort, charac-
terized as low, involves training the operators to use the
stop button more efficiently. The system is redundant so
training is only required once. The effect: unnecessary
cooling can be reduced, which results in advantages in
terms of energy and economy.
& In Option 3, the pipes between the WFI distillation col-
umns in PKau, the column heads and theWFI storage tank
covers are insulated. As an effect, this improvement will
Effort
Low High
Effect
High
1
4
6
7
8
9
10
12
Installing enthalpy control (↓ CW, ↑ steam)
Installing nitrogen evaporator
(↓ H2O-ethylene glycol)
Reducing air change rate (entire area 
overnight) (↓ elec.; not considered: ↑↓ CW, 
↓ steam)
Reducing air change rate (entire production 
area) (↓ elec.; not considered: ↑↓ CW, 
↓ steam)
Reducing air change rate (storage rooms) 
(↓ elec.; not considered: ↑↓ CW, ↓ steam)
Installing additional heat exchanger in WFI 
subloop (↓ CW, ↓ steam)
Reducing HVAC pressure (↓ elec.)
Installing additional heat exchanger in purified
water subloop (↓ CW, ↓ steam)
Low
2
3
11
Training operators to use WFI subloop stop 
button (↓ CW, ↓ steam)
Insulating pipes in WFI distillation system 
(↓ CW, ↓ steam; not considered: ↓ elec.)
Reducing laminar flows in isolators overnight
(↓ elec.; not considered: ↓ CW, 
↓ steam)
5 Recovering cold energy from liquid nitrogen
exhaust of lyophilizer (↓ H2O-ethylene glycol)
Fig. 4 Characterizing generated
options in Phase I with “↑”, “↓”,
CW and elec. representing
increase in consumption,
reduction in consumption,
cooling water and electricity,
respectively
J Pharm Innov (2014) 9:212–226 219
reduce the loss of heating energy of the columns and
cooling energy for maintaining the room temperature of
the room where the columns are located. Additional ef-
fects include improved safety as a result of fewer hot
surfaces and improved workplace conditions as a result
of the lower room temperature.
& In Option 4, energy from the nitrogen evaporator for the
gaseous nitrogen supply is used. In the current state the
cold energy is blown into the environment and not col-
lected. Option 5 uses the cold energy after the phase
change that is not consumed by the lyophilizer. In both
options, the cooling energy would be collected in heat
exchangers and returned to the H2O-ethylene glycol loop,
reducing the cooling requirements of the building.
& In Options 6–8, the air change rate is reduced in different
scenarios to save electricity, purified steam and cooling
water. Option 6 reduces the air change rate in the whole
building overnight by introducing a system with two
operation modes, i.e., a normal mode and a standby mode
for night-time use. The air change rate would be perma-
nently reduced with Option 7 in the production area and
with Option 8 only in the storage rooms. All three options
were calculated for a reduction of the air change rate of
10 %, resulting in an attractive reduction (approx. 30 %).
As it can be seen in the Sankey diagram in Fig. 3, a huge
part of PKau’s electricity is consumed by the HVAC
system, which gives this option a high potential for sav-
ings. Consequently, it is listed as a high-level effect in
Fig. 4. The changed cooling and humidification perfor-
mance was not considered in Phases I+II as this would
require exact simulations, which were not carried out until
Phase III.
& In Option 9, a new heat exchanger is installed between the
valve and the heater in the WFI subloop, saving steam,
and cooling water. The idea of this measure is transferred
to Option 12 where purified water is heated from 20 °C to
80 °C.
& Option 10 reduces the HVAC pressure by 1 % from 600 to
594 Pa overpressure to save electricity since the pressure
is set higher than the simulated values to prevent problems
with pressure drops.
& Option 11 reduces laminar flows in the isolators for aseptic
filling by 10 % from 0.450 to 0.405 m/s overnight when
no production takes place, including the assumptions for
Options 6–8.
Figure 4 shows the summary and the classification of the
options in Phase I in a matrix showing the effort required and
effect of the implementation. No option was classified in the
category of low effort with high effect, which would have
been the most preferable case, suggesting that the most prom-
ising options have already been implemented and that
Engineering worked well during the design stage. Eight op-
tions were evaluated as high effect with high effort, e.g.,
Option 1’s level of investment is high and GMP problems
are expected. The effect: a high level of financial and energy
benefit because the HVAC system is the largest energy con-
sumer in the building (see Fig. 3). The ideas on adjusting the
air change rate, i.e., Options 6 to 8, would require clarification
onGMP risk, which was ranked as high effort, while the effect
could be high energy and cost savings. Similarly, Options 10
and 11 are GMP relevant as the ventilation systems are
changed. Options 4 and 5 are technically feasible and
provide high financial and energy savings. However,
the energy could only be recovered inconstantly since
the energy can only be used when the system is running
(not periodic, on/off operation). Only Option 5 was
classified in the low effort and low effect category as
it could be implemented without high GMP risk and
investment, but resulted in low savings.
Part of
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Fig. 5 Option 1: enthalpy control
system as a representative
generated option
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Although no decision or selection is forced in Phase I, a
qualitative classification of the priorities was made based on
Fig. 4. The preferred optimum is the low effort/high effect
category, followed by both the low effort/low effect and high
effort/high effect options, whereas the option in high effort
and low effect is third priority. Thus, there is no option ranked
as first priority, the second priority ones were tackled first in
Phase II and then the third priority one. In our case study, no
measure was eliminated in this phase because no measure was
considered to be completely infeasible.
Phase II
After each option was designed as described in “Phase II:
Evaluate and Eliminate Options”, each one was evaluated for
the first time according to the multiobjective indicators of
Phase II in Fig. 1, and then normalized using Eq. 1. For the
qualitative evaluation the scoring system for the GMP,
workers’ safety, and workplace conditions in Table 1 is used.
For the selection of the best and elimination of inferior op-
tions, two different but equivalent visualization aids were
used: a spider diagram (Fig. 6) and “heat map” (Table 2). In
The spider diagram in Fig. 6 is proposed for the selection of
the best options in Phase III and was preferably used in this
case study. The evaluation indicators are shown from 0 to
100 % on the axis.
The heat map in Table 2 is a further tool for the identifica-
tion of the Pareto optima using the color scheme of Table 1 to
highlight the differences between the normalized values with
regard to the various options and criteria. For this project, the
absolute values were assigned a color scheme and then this
color scheme was also used for the relative values. The color
scheme in Table 1 can be individually adapted to suit the
company’s requirements.
The best and worst option in each category can be identi-
fied from Fig. 6 and Table 2. This information was crucial for
the following Pareto optimization:
& In the 1/Investment criterion, Option 2 is the best because
of the short training time for the operators while Option 6,
which requires drastic changes in the ventilation system, is
rated as the worst.
& The highest energy savings are achieved byOption 6 since
the ventilation system is the largest consumer in the build-
ing. On the other hand, Options 5 and 12 have the lowest
savings since there is only little potential from the nitrogen
exhaust air and the purified water subloop is rarely used.
& The highest cost savings result from Option 1, the enthal-
py control system, which saves immense amounts of
cooling, and the lowest from Option 12 as the purified
water subloop is rarely used.
& In the GMP criterion, seven ideas are considered to be
“high risk” or GMP=1, which is 33 % in Fig. 6 and
Table 2 because the maximum score was 3, i.e., none of
the options improved GMP conditions. Options 6–8 to
reduce the air change rate either violate GMP regulations
or their effects on particle and microbiological concentra-
tions in clean rooms cannot be estimated, which is
also valid for Option 11 and the isolators, respec-
tively. For Options 9 and 12 it remains unknown if
the GEP (good engineering practice) of having tur-
bulent flow in the whole system will still be valid
after implementation and for Option 10 it cannot be
guaranteed that the pressure differences between the
zones can be maintained.
& Safety is increased by Option 3 because hot pipes, tank
covers and other hot surfaces are insulated, significantly
lowering the probability of burns.
GMP=1
Fig. 6 Evaluating and eliminating options in Phase II: a normalized indicator values eA and for investment eA−1 of all 12 options; b result after
eliminating options with GMP=1 (high risk on product quality); c Pareto optimal options
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both, values of A are reported in the range of [0, 1] and the
investment criterion is inverted to have the maximum and
preferred values and thus best option as the highest value.
& The workplace conditions in Options 6–8 are positively
affected as the reduction of the air change rate also reduces
the noise and the draftiness of the ventilation system.
For a systematic and automated selection process of the most
promising and the elimination of non-suitable options, the fol-
lowing elimination algorithm was used in this case study:
1. Only measures evaluated in each criterion are considered.
2. Options that are “high risk” for GMP conditions (GMP=1)
are eliminated.
3. Pareto analysis of the remaining options: Pareto optima
are passed on to Phase III as first priority; Pareto inferior
options remain in this phase and are passed on at a later
point in time as second priority and stored in the knowl-
edge database.
For execution of this algorithm in this case study, only the 12
fully evaluated measures were considered in the spider diagram
in Fig. 6 and the heat map in Table 2 as well as for Pareto
optimization. Of the 12 fully evaluated options in Fig. 6a, the 7
options with GMP=1 (red circle) were eliminated because in
the pharmaceutical industry, no “high risks” for GMP condi-
tions are desired. Of the remaining Options 1–5 in Fig. 6b,
Option 5 can be identified as Pareto inferior as this option is
equal to or worse than Options 3 and 4. Figure 6c shows Pareto
optima 1–4. These optima are all equal, accepted, and passed
on to Phase III for amore delineated design and evaluation. The
same elimination process can be performed using the heat map
shown in Table 2, where the measures have first been sorted by
Pareto optima, Pareto inferior and GMP=1 options for better
readability. The latter options can be identified as they are
highlighted in red and are therefore eliminated. Looking at
Options 3–5, one can see that Option 5 is always equal to or
worse than Options 3 and 4, making it Pareto inferior and thus
deferred. Option 5 was already evaluated as Pareto inferior in
Phase I, and this rough classification is later verified.
Phase III
The four remaining options from Phase II were delineated
more extensively and then evaluated according to the evalua-
tion criteria in Phase III: the NPVand risk regarding safety and
GMP.
In Fig. 7, the results of the above evaluation of all 4 options
are shown with the NPV on the abscissa and the Maximum
RPN from the FMEA on the ordinate. The NPV is calculated
using Eq. 2, with the number of years n and the discount rate r
taken from a company internal guideline. It can be seen in
Fig. 7 that no option has a negative NPV. Option 1 has the
highest one as it saves large amounts of energy at a compara-
bly low investment cost, whereas Option 3 has the lowest
NPV because of its lower benefit. The GMP and safety risk
are combined and evaluated by means of an FMEA according
Table 2 “Heat map” representation of evaluation results with values of eA and eA−1 based on color code for evaluation indicators used in Phase II
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Fig. 7 Evaluation results of the options in Phase III for the identification
of Pareto optima
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to “Phase III: Identify Optimum Options” and a company
internal guideline for scaling Severity, Occurrence, and
Detectability. For example, the maximum risk of Option 1 is
represented by a failure mode where the temperature of the
clean room is influenced by outside temperature fluctuations.
According to the Roche guideline, a Severity of 2 was
achieved because the temperature in the HVAC system does
not have an influence on product quality since the isolator’s
after-cooling protects the product. As temperature fluctuations
occur constantly, no prevention measures were chosen,
resulting in an Occurrence of 10. Because the clean room
monitoring system as well as the temperature control system
detect any problems with regard to temperature, Detectability
was set to 2. The RPNs were then calculated using Eq. 3,
resulting in an RPN of 40 for the above-mentioned failure
mode in Option 1. The maximum value of all RPNs is termed
“Maximum RPN” and it is the one with the greatest adverse
effect on product quality or workers’ safety. In the case of
Option 1, the Maximum RPN was the above-mentioned ex-
ample with the temperature fluctuations. For the other three
options, the same procedure was applied, resulting in the
highest value for Option 4 because of the difficult implemen-
tation and lack of experience. Because of this uncertainty
combined with high risk, this option was rejected by QA
and not passed on for implementation. It is stored as an idea
for future implementation.
A maximum NPV and minimum GMP and safety risk is
desired, thus Options 1 and 2 are Pareto optima because they
superimpose Option 3 and the eliminated Option 4 in both
criteria. As sufficient engineering capacity and budget was
available, all options were passed on with Options 1 and 2 as
priority 1 and Option 3 as priority 2.
Phase IV
In Phase IVafter finalizing the design, the budget and timeline
were set up and the three options passed on from Phase III
were implemented.
The implementation itself and its results as well as post-
implementation control for the four options in Phase III are
different for each measure: the enthalpy control system
(Option 1) was implemented in one of the HVAC systems
because the timeline was suitable, and it is running according
to all regulations. The stepwise introduction in the other
systems will be performed after enough experience has been
gained from this first system and after its effectiveness and
feasibility have been confirmed. Operators have been trained
for Option 2, but it has not been realized to full our satisfaction
as the button could be used evenmore efficiently. Option 3 has
been implemented with complete success as safety has in-
creased drastically because most of the hot surfaces are cov-
ered and the temperature in the room decreased significantly,
improving workplace conditions for the operators’ benefit.
Phase V
Phase Vanalyzed the results of the implementation, the extent
to which they meet expectations and the replication potential.
Within the scope of knowledge management, options which
are not passed on/eliminated are stored together with the
experiences made in connection with implementation. All of
these options are revisited and reinvestigated, and may be
implemented.
Figure 8 shows the business results of this case study as
unweighted energy consumption using a “before and after”
comparison. After the implementation of the proposed
Options 1–3, PKau energy consumption is reduced by 2.4 %
using the EWF and 12.9 % in unweighted numbers. The
preliminary results reported elsewhere [35] have been up-
dated. Most of the reduction is with regard to cooling water,
which is energy non-intensive to produce as a free-cooling
unit can be used (EWF<1GJ/GJ), whereasmore steam, which
is energy intensive, is needed for the humidification (EWF>1
GJ/GJ).
In Phase V, the replication potential of each alternative was
evaluated. Option 1, the enthalpy control system, already uses
experience from other buildings and the lessons learnt from
this implementation will be transferred to other projects.
Option 2 is PKau-specific and cannot be replicated in other
buildings; however, it is possible to apply the concept if the
purified water subloop is used more often. The positive expe-
rience and results of Option 3 can be easily transferred to other
buildings and sites. For Option 4, the replication potential is
limited since it has not been implemented for PKau, but
possibilities for other buildings and sites will be investigated.
The working processes and outcomes of the project were
reported to the upper management of Engineering in order to
ensure the possibility of implementation.
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Conclusions and Outlook
In this article, we have presented a novel framework for
energy optimization in a pharmaceutical plant. Its overall
purpose is to (a) support a design set of optimal energy-
saving solutions, (b) execute the implementation and (c) com-
pare the plan and the result as post-implementation feedback.
The possible energy efficiency measures are first generated
and then the best ones are selected for implementation in a
stepwise screening process. Multiobjective evaluation criteria
covering financial and non-financial aspects are defined to
account for the comprehensive benefits of energy conserva-
tion. To support a systematic and non-subjective decision-
making process, Pareto optimization is used as a way of
allowing a trade-off between the various multiobjective eval-
uation criteria. The framework is based on specific elements
for the pharmaceutical sector, e.g., GMP, risk analysis and the
stakeholders in pharmaceutical production. During the whole
process a RACI scheme defines the rights and responsibilities
of the various stakeholders. The importance of GMP in the
pharmaceutical industry is reflected by the use of risk analysis
tools, e.g., the industry standard FMEA, to discover and
prevent any negative impact on product quality.
This framework was executed in an industrial case study on
the parenterals production factory of Hoffmann-La Roche Ltd.
in Kaiseraugst, Switzerland, proofing the concepts for screen-
ing measures, the stepwise selection and the exact definition
of roles and responsibilities. Starting with 12 generated energy
efficiency options, the 3 best ones were chosen using a step-
wise selection process and implemented. These three options
show the best multiobjective performance and do not have any
negative impact on GMP regulations or quality. This screen-
ing concept made it possible to rapidly evaluate many mea-
sures and only select the best ones. In cases of limited
engineering capacity or budget, this may be important
because resources such as capacity or budget can be used
very efficiently by focusing on the measures individually.
To support this generation and selection process, various
visualization methods were presented. The non-selected
ideas are stored in a knowledge database so that the idea
for the measures and the invested time are not lost.
According to the concept of continuous improvement,
these ideas can be reconsidered at any time for future
implementation. The business results showed that a re-
duction of energy consumption of 2.4 % using the EWF
concept is even possible in a brand new factory. During
the execution of the framework, the defined roles and
rights for all stakeholders from the RACI scheme facili-
tated effective communication among the teams of QA,
Operations, Engineering, and Finance.
The framework is kept generic so that it can be applied to
other plants, sites and companies independent of the technol-
ogy used to manufacture drug substance or drug product. This
means that only minor modifications are required for adapta-
tion to different situations, e.g., RACI in particular. It may also
be possible to use the framework for media optimization and
in other GMP-relevant industries, e.g., the medical technology
or food industries as they have similar requirements. In the
future, these applications will have to be tested in further
industrial case studies.
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Appendix
Option 1 is the installation of the enthalpy control system
shown in Fig. 5. The heat recovery unit consists of two heat
exchangers: at outside temperatures of <12 °C the heating
energy from the exhaust air from the clean rooms can be
transferred to the supply air; at hot outside temperatures
>30 °C cooling energy from the exhaust air from the clean
rooms can be transferred to the supply air. Because of hygienic
aspects, an outside air to supply air ratio of α≥0.3 has to be
guaranteed. The recirculated air system can recirculate 1−α of
the exhaust air to save heating, cooling and humidification
while α comes from the outside air and is used for the supply
air which flows through the second part of the heat recovery
unit, the cooling unit, the fan, the humidification unit and the
heating unit. The conditions in the clean room with 30–60 %
RM (relative humidity) and 18–25 °C are constraints from the
GMP regulations that have to be fulfilled at all times and
reduce the degree of freedom in the operation. Without the
enthalpy control system, the air recirculation is set to a fixed
value and the heat recovery unit works at an energetically non-
optimum operating point. The enthalpy control system col-
lects the temperature and humidity data from the outside air
and the exhaust air from the clean rooms and using the heat
recovery and the recirculated air system, it tries to reduce
energy consumption in the cooling, humidification and
heating unit by calculating the enthalpy of different operating
modes and using the optimum one. The main benefit of the
enthalpy control system is generated in spring and autumn
when the outside air has a humidity and temperature similar to
clean room conditions because then it is possible to operate
the HVAC system without heating, cooling and humidifica-
tion by using 100 % outside air and the heat recovery unit for
the air conditioning. In winter and summer, the maximum
recirculating air ratio of α has to be used. In winter the air is
dry and cold, thus a large amount of energy has to be used for
heating and humidification, and in summer the air is hot and
humid, thus a large amount of cooling energy for cooling and
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dehumidification is lost. For this option a trade-off between
cooling water and purified steam has to be made because a lot
of cooling can be saved whereas more purified steam for
humidification is consumed.
References
1. Bundesamt für Energie. Überblick über den Energieverbrauch
der Schweiz im Jahr 2010. Ittigen (Switzerland): BBL/
Bundespublikationen; 2010.
2. Galitsky C, Chang S, Worrell E, Masanet E. Energy efficiency
improvement and cost saving opportunities for the pharmaceutical
industry: An ENERGY STAR® Guide for energy and plant man-
agers. Berkeley: Ernest Orlando Lawrence Berkeley National
Laboratory; 2008.
3. Dow Jones Sustainability Indexes. http://www.sustainability-
indexes.com/. Accessed 19 Sept 2012.
4. Sugiyama H, Fischer U, Hungerbühler K, Hirao M. Decision frame-
work for chemical process design including different stages of envi-
ronmental, health and safety assessment. AIChE J. 2008;54:1037–
53.
5. Chen H, Shonnard DR. Systematic framework for environmentally
conscious chemical process design: early and detailed design stages.
Ind Eng Chem Res. 2004;43:535–52.
6. Hoffmann VH, McRae GJ, Hungerbühler K. Methodology for early-
stage technology assessment and decision making under uncertainty:
application to the selection of chemical processes. Ind Eng Chem
Res. 2004;43:4337–49.
7. Hoffmann VH, Hungerbühler K, McRae GJ. Multiobjective screen-
ing and evaluation of chemical process technologies. Ind Eng Chem
Res. 2001;40:4513–24.
8. Albrecht T, Papadokonstantakis S, Sugiyama H, Hungerbühler K.
Demonstrating multi-objective screening of chemical batch process
alternatives during early design phases. ChemEng Res Des. 2010;88:
529–50.
9. Heinzle E, Weirich D, Brogli F, Hoffman VH, Koller G, Verduyn
MA, et al. Ecological and economic objective functions for screening
in integrated development of fine chemical processes. 1. Flexible and
expandable framework using indices. Ind Eng Chem Res. 1998;37:
3395–407.
10. Koller G, Weirich D, Brogli F, Heinzle E, Hoffmann VH, Verduyn
MA, et al. Ecological and economic objective functions for
screening in integrated development of fine chemical process-
es. 2. Stream allocation and case studies. Ind Eng Chem Res.
1998;37:3408–13.
11. Van der Vorst G, Aelterman W, De Witte B, Van Langenhove H.
Assessment of the integral resource consumption of individual chem-
ical production processes in a multipurpose pharmaceutical produc-
tion plant: a complex task. Ind Eng Chem Res. 2009;48:5344–50.
12. Raymond MJ, Slater CS, Savelski MJ. LCA approach to the analysis
of solvent waste issues in the pharmaceutical industry. Green Chem.
2010;12:1826–34.
13. Bieler PS, Fischer U, Hungerbühler K. Modeling the energy con-
sumption of chemical batch plants—top-down approach. Ind Eng
Chem Res. 2003;42:6135–44.
14. Bieler PS, Fischer U, Hungerbühler K. Modeling the energy con-
sumption of chemical batch plants—top-down approach. Ind Eng
Chem Res. 2004;43:7785–95.
15. Szijjarto A, Papadokonstantakis S, Fischer U, Hungerbühler K.
Bottom-up modelling of the steam consumption in multipurpose
chemical batch plants focusing on identification of the optimization
potential. Ind Eng Chem Res. 2008;47:7323–34.
16. Shamkishore L, Manmadha Reddy K, Pathy A. Energy Conservation
in Pharmaceutical Manufacturing. Pharmaceutical Technology
Sourcing and Management. 2011;7(11): online publication. http://
www.pharmtech.com/pharmtech/Energy-Conservation-in-
Pharmaceutical-Manufacturin/ArticleStandard/Article/detail/
747409. Accessed 05 Dec 2012.
17. Liu H. Improving energy efficiency in a pharmaceutical
manufacturing environment—analysis of EUI and cooling
load. Master Thesis – Massachusetts Institute of Technology.
2009. http://hdl.handle.net/1721.1/55229. Accessed 05 Dec 2012.
18. Graf C. Energieeffizente Herstellung von Pharmawasser. Pharm Ind.
2010;72:1797–803.
19. Zhi-dong L, Shu-shen Z, Yun Z, Yong Z, Wei L. Evaluation of
cleaner production audit in pharmaceutical production industry: case
study of the pharmaceutical plant in Dalian, P. R. China. Clean Tech
Environ Policy. 2011;13:195–206.
20. Jacka JM, Keller PJ. Business process mapping: improving customer
satisfaction. 2nd ed. Hoboken: Willey; 2009.
21. Biegler LT, Grossmann IE, Westerberg AW. Systematic methods of
chemical process design. New Jersey: Prentice Hall; 1997.
22. Howat CS. Analysis of plant performance. In: Perry RH, Green DW,
editors. Perry’s chemical engineers’ handbook. 7th ed. New York:
McGraw-Hill; 1997.
23. Wernet G, Conradt S, Isenring HP, Jiménez-González C, Hungerbühler
K. Life cycle assessment of fine chemical production: a case study of
pharmaceutical synthesis. Int J Life Cycle Assess. 2010;15:294–303.
24. Jiménez-González C, Curzons A, Constable D, Cunningham V.
Cradle-to-gate life cycle inventory and assessment of pharmaceutical
compounds. Int J LCA. 2004;9:114–21.
25. Jiménez-González C, Overcash M. Energy sub-modules applied
in life-cycle inventory of processes. Clean Prod Process. 2000;2:
57–66.
26. Huijbregts M, Rombouts L, Hellweg S, Frischknecht R, Hendriks J,
van de Meent D, et al. Is cumulative fossil energy demand a useful
indicator for the environmental performance of products. Environ Sci
Technol. 2006;40:641–8.
27. The Intergovernmental Panel on Climate Change. Climate Change
2007. 2007. http://www.ipcc.ch/ipccreports/ar4-wg1.htm.
28. Verein Deutscher Ingenieure. VDI-Richtline 4600: Cumulative ener-
gy demand, terms, definitions, methods of calculation. Düsseldorf:
Verein Deutscher Ingenieure; 1997.
29. U.S. Environmental Protection Agency. ENERGY STAR
Performance Ratings - Methodology for Incorporating Source
Energy Use. U.S. Environmental Protection Agency. March 2011.
http://www.energystar.gov/ia/business/evaluate_performance/site_
source.pdf. Accessed 19 Sept 2012.
30. International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use.
ICH Harmonised Tripartite Guideline: Quality Risk Management
Q9. Step 4. 9 Nov 2005. http://www.ich.org/fileadmin/Public_
Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_
Guideline.pdf
31. International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use.
ICH Harmonised Tripartite Guideline: Pharmaceutical Quality
System Q10. Step 4. 4 Jun 2008
32. Sugiyama H, Sukowski L, Schmidt R. “Japan Quality” in pharma-
ceutical technical operations. Part I: understanding differences in
quality expectations between Western and Japanese markets. Pharm
Ind. 2011;73:754–8.
33. Sugiyama H, Sukowski L, Schmidt R. “Japan Quality” in pharma-
ceutical technical operations. Part II: building a blueprint for better
performance in the Japanese market. Pharm Ind. 2011;73:912–8.
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/
Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf. Accessed 03
Mar 2014.
J Pharm Innov (2014) 9:212–226 225
34. Sugiyama H, Schmidt R. Realizing Continuous Improvement in
Pharmaceutical Technical Operations - Business Process Model in
Roche’s Parenterals Production Kaiseraugst. In: Bogle I D L,
Fairweather M, editors. 22nd European Symposium on Computer
Aided Process Engineering, Elsevier; 2012. 422–6.
35. Sugiyama H, Schinzel S, Müller G, Schmidt R. Applying
process systems engineering for continuous improvement in
pharmaceut ical product ion. Proceedings of the 6th
International Conference on Process Systems Engineering
(PSE ASIA). 2013; 600–5
226 J Pharm Innov (2014) 9:212–226
